• New antitumor response information from a variety of doses and regimens unveiled at present at Incyte (NASDAQ:) investor occasion
• These outcomes construct upon security and tolerability information introduced earlier at present throughout a mini-oral presentation on the European Society of Medical Oncology (ESMO) Congress 2024
• Findings assist the initiation of a pivotal trial in ovarian most cancers, anticipated to start in 2025; further plans to guage INCB123667 together with different remedies are underway

WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) at present introduced new early scientific information for INCB123667, a extremely selective, potential first-in-class CDK2 inhibitor, in sufferers with superior strong tumors. The trial outcomes, introduced throughout a mini-oral presentation on the European Society of Medical Oncology (ESMO) with new, up to date information shared through the Firm’s investor occasion, spotlight the potential of INCB123667 as a differentiated remedy possibility for cancers with elevated Cyclin E1 exercise, amplification and/or overexpression in cells predictive of CDK2 dependency.

Within the trial, sufferers with superior or metastatic strong tumors (n=205) “ together with ovarian most cancers, endometrial most cancers, gastrointestinal most cancers, HR+/HER2- breast most cancers and triple adverse breast most cancers, amongst others “ obtained various doses of INCB123667 starting from 50mg to 150mg utilizing once-daily (QD) and twice-daily (BID) dosing schedules.

New information from the Part 1b dose growth portion of the trial (information cut-off August 26, 2024) introduced at present throughout Incyte’s investor occasion, reveal single-agent antitumor exercise, and reduces in circulating tumor DNA (ctDNA) throughout a variety of doses and regimens, notably in sufferers with ovarian most cancers and endometrial most cancers whose tumors overexpress Cyclin E1. The trial is ongoing, and the information will proceed to mature.

• Of the 37 evaluable members with platinum-resistant ovarian most cancers handled at three (3) chosen dose ranges (50mg BID, 100mg QD and 125mg QD) within the growth portion of the trial, 9 members (24.3%) skilled an general response (OR; 2 full responses [CR] and seven partial responses [PRs]). The best OR price of 31.3% (5 responders, together with 2 CRs) was discovered within the 50mg BID cohort (16 evaluable members). Moreover, a illness management price (DCR) of 75.7% (28/37) was achieved in sufferers with ovarian most cancers.
• As well as, 4 PRs had been reported amongst sufferers with endometrial most cancers.

The early-stage scientific exercise of INCB123667 represents an thrilling and promising breakthrough for sufferers with ovarian most cancers. We imagine this novel CDK2 inhibitor has the potential to be a foundational remedy for platinum-resistant ovarian most cancers, providing a brand new and differentiated remedy for sufferers who at present have restricted remedy choices, stated Pablo Cagnoni M.D., President, Head of Analysis and Improvement, Incyte. We stay up for advancing the event of INCB123667 for the remedy of sufferers with ovarian most cancers each as a single agent and together.

The Half 1b information construct on outcomes from the dose escalation portion (Half 1a) of the trial evaluating the security and tolerability of INCB123667 introduced throughout a mini-oral presentation (Mini oral session: Developmental therapeutics) at ESMO.

Outcomes from the Half 1a dose escalation portion of the trial (information cut-off July 15, 2024) embody:

• INCB123667 demonstrated a manageable security profile (n=84). The commonest hematologic treatment-related adversarial occasions (TRAEs) had been thrombocytopenia (35%, 13% Grade 3), anemia (30%, 7% Grade 3) and neutropenia (26%, 8% Grade 3). The commonest non-hematologic TRAEs had been nausea (42%), fatigue (23%) and vomiting (17%); all of which had been Grade 1 and a couple of besides one case of Grade 3 vomiting and one case of Grade 3 fatigue.
• Robust selective inhibition of CDK2 was noticed leading to circulating tumor DNA (ctDNA) discount in any respect dose ranges. Throughout dose escalation, 39 out of 48 sufferers who had ctDNA measurements at cycle 1, day 1 and cycle 2, day 1 confirmed reductions in ctDNA.

Outcomes from this examine introduced at present at ESMO reinforce the concept that the novel and extremely selective CDK2 inhibitor INCB123667 could present a possible new remedy possibility for cancers with elevated Cyclin E1 signaling (CCNE1 amplification and Cyclin E1 overexpression), predictive of CDK2 dependency, stated Dr. Matteo Simonelli, Head of Early-Drug Improvement in Stable Tumors at IRCCS Humanitas Analysis Hospital. The information converse to the potential of INCB123667 as an lively and selective focused remedy for various most cancers varieties, notably ovarian most cancers, and I stay up for seeing additional ends in later phases of growth.

The examine is ongoing. Plans are underway to provoke a pivotal examine in ovarian most cancers subsequent 12 months and consider INCB123667 together with different remedies.

Convention Name and Webcast Info

Incyte will host an in-person analyst and investor occasion at present from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) to debate key information shows at ESMO together with information from the POD1UM-303 Presidential Symposia and its CDK2 inhibitor program. The CDK2 information will embody up to date outcomes from a later information cut-off, in addition to the information included within the ESMO accepted summary and mini-oral presentation.

To entry the convention name, please dial 877-407-8037 for home callers or +1 201-689-8037 for worldwide callers. When prompted, present the convention identification quantity, 13748627.

The convention name may also be webcast reside and could be accessed at investor.incyte.com.

Concerning the Trial (NCT05238922)

This open-label, dose-escalation and dose-expansion Part 1 examine is evaluating the security, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of INCB123667 when administered as monotherapy on the advisable dose for growth (RDE[s]) in members with chosen superior or metastatic strong tumors. Half 1A (dose escalation) decided the advisable dose of INCB123667 for growth and the utmost tolerated dose (MTD). Half 1B (cohort dose growth part) will additional discover antitumor exercise of INCB123667 as a monotherapy in six tumor-specific cohorts on the RDEs outlined in Half 1A.

For extra details about the examine, please go to: https://clinicaltrials.gov/examine/NCT05238922.

About INCB123667

INCB123667 is a novel, potent and selective oral small molecule inhibitor of CDK2 which has been proven to suppress tumor progress as monotherapy and together with commonplace of care, in Cyclin E amplified tumor fashions. Cyclin E amplification and overexpression has been reported to be related to CDK4/6 resistance and poor scientific outcomes in ovarian, gastric, endometrial and breast cancers. INCB123667 has the potential to be a extremely focused and efficacious remedy for superior strong tumors, together with gynecologic tumors, endometrial, uterine, gastric and triple adverse breast most cancers, amongst others.

About Incyte

A worldwide biopharmaceutical firm on a mission to Clear up On., Incyte follows the science to seek out options for sufferers with unmet medical wants. By means of the invention, growth and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for sufferers and a powerful pipeline of merchandise in Oncology and Irritation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For extra info on Incyte, please go to Incyte.com or observe us on social media: LinkedIn, X, Instagram, Fb (NASDAQ:), YouTube.

Incyte Ahead-looking Statements

Apart from the historic info set forth herein, the issues set forth on this press release, together with statements concerning the presentation of information for Incyte’s CDK2 inhibitor (INCB123667), the potential this CDK2 inhibitor gives for sufferers, and expectations concerning ongoing and future scientific trials include predictions, estimates, and different forward-looking statements.

These forward-looking statements are primarily based on our present expectations and are topic to dangers and uncertainties which will trigger precise outcomes to vary materially, together with unanticipated developments in and dangers associated to: unanticipated delays; additional research and growth and the outcomes of scientific trials probably being unsuccessful or inadequate to fulfill relevant regulatory requirements or warrant continued growth; the power to enroll ample numbers of topics in scientific trials and the power to enroll topics in accordance with deliberate schedules; determinations made by the FDA and regulatory businesses outdoors of america; the efficacy or security of our merchandise; the acceptance of our merchandise within the market; market competitors; surprising variations within the demand for our merchandise and the merchandise of our collaboration companions; the results of introduced or surprising price regulation or limitations on reimbursement or protection for our merchandise; gross sales, advertising, manufacturing, and distribution necessities, together with our potential to efficiently commercialize and construct business infrastructure for newly authorized merchandise and any further new merchandise that turn into authorized; and different dangers detailed on occasion in our stories filed with the U.S. Securities and Alternate Fee, together with our annual report on Type 10-Okay and our quarterly report on Type 10-Q for the quarter ended June 30, 2024. We disclaim any intent or obligation to replace these forward-looking statements.

View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240914564406/en/

Incyte Contacts:
Media
media@incyte.com

Buyers
ir@incyte.com

Supply: Incyte